Wedbush Assumes Coverage on Cardica, Inc. (CRDC) at Outperform; Recent Financing Provides Cash for Key Upcoming Milestones

March 27, 2012 1:12 PM EDT
Get Alerts CRDC Hot Sheet
Price: $2.35 --0%

Rating Summary:
    1 Buy, 1 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush assumes coverage on Cardica, Inc. (NASDAQ: CRDC) with an Outperform. PT $5.00 (from $6).

Analyst, Akiva Felt, said, "2012 has the potential to be a breakout year for Cardica as the company is poised for multiple catalysts related to its promising Microcutter product line, including: (1) CE Mark for XCHANGE30 expected in the next 1-3 weeks; (2) re-start of European clinical trial for XCHANGE30 in CQ2:12; (3) feedback from European surgeons following XCHANGE30 soft-launch around mid-year; and (4) results from the Microcutter European clinical trial followed by US 510(k) submission in H2:12."

For an analyst ratings summary and ratings history on Cardica, Inc. click here. For more ratings news on Cardica, Inc. click here.

Shares of Cardica, Inc. closed at $2.05 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst PT Change, New Coverage